Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) EBT: 2016-2024

Historic EBT for Organogenesis Holdings (ORGO) over the last 9 years, with Dec 2024 value amounting to -$2.8 million.

  • Organogenesis Holdings' EBT rose 263.39% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.2 million, marking a year-over-year increase of 58.24%. This contributed to the annual value of -$2.8 million for FY2024, which is 127.01% down from last year.
  • As of FY2024, Organogenesis Holdings' EBT stood at -$2.8 million, which was down 127.01% from $10.4 million recorded in FY2023.
  • Over the past 5 years, Organogenesis Holdings' EBT peaked at $63.1 million during FY2021, and registered a low of -$2.8 million during FY2024.
  • Moreover, its 3-year median value for EBT was $10.4 million (2023), whereas its average is $9.3 million.
  • Its EBT has fluctuated over the past 5 years, first spiked by 255.13% in 2021, then slumped by 127.01% in 2024.
  • Over the past 5 years, Organogenesis Holdings' EBT (Yearly) stood at $17.8 million in 2020, then surged by 255.13% to $63.1 million in 2021, then tumbled by 67.85% to $20.3 million in 2022, then slumped by 48.76% to $10.4 million in 2023, then crashed by 127.01% to -$2.8 million in 2024.